Endocrine Abstracts

IntroductionMerkel cell carcinoma-MCC) is a rare, aggressive, neuroendocrine skin tumor with a poor prognosis. Chemotherapy (CT) and/or local/locoregional radiotherapy (LRRT) are first-line MCC therapies, but disseminated/locally advanced MCCs often become resistant to this treatment. The use of programmed cell death receptor1/programmed cell death ligand 1 (PD-1/PD-L1) monoclonal antibodies is a new type of therapy for MCC. While PD-1 monoclonal antibod...